Commodity molecules sell a price. Specialty molecules sell a spec.
The paracetamol in this morning's tablet, the paint on your wall, the pesticide sprayed on the wheat in your bread, the foam in your car seat: each one began as a specific molecule built in a chemical reactor. A chemicals company sells the molecules that everything else is made from. But the name hides two completely different businesses. One makes standard, bulk molecules like caustic soda or soda ash, where the product is identical to a rival's and the world sets the price; this is commodity chemicals, and it lives and dies by the cycle. The other makes complex, made-to-order molecules to a single customer's exact specification, an intermediate for one particular drug or crop chemical; this is specialty chemicals, and once your molecule is designed into the customer's product, replacing you is slow, risky, and expensive. The whole game is knowing which of the two you are looking at, because they earn money in opposite ways.
A new molecule is made, the customer puts it through months of qualification, it gets designed into their product and their regulatory filings, that lock turns into a stream of repeat orders no rival can easily interrupt, and the repeat orders become cash. The switching cost is the whole moat.
Specialty, locked-in, ROCE-positive, durable, compliant, and you are looking at a compounder rather than a cyclical trade.
Answer these six and you have understood the industry. The rest of the page is the detail behind them.
Chemicals is not one industry but two, wearing the same lab coat. Tell them apart and everything else on this page follows.
If two plants make the exact same caustic soda, who decides the price? Neither of them. The world does, through global supply and whatever new capacity China has just switched on. That is commodity chemicals: your output is identical to a rival's, you are a price-taker, and your margin swings with the cycle. Specialty chemicals is the opposite. You make a molecule to one customer's exact recipe, an intermediate that goes into a single patented drug or crop chemical, and it cannot be bought off any shelf. There you are closer to a price-setter, because the customer needs your specific molecule, not just any molecule.
To win a specialty molecule, the customer runs your process through months, sometimes years, of qualification: testing purity, consistency batch after batch, and whether it fits their regulatory filings. Once you pass and your molecule is written into their product's specification, switching to a cheaper rival means re-qualifying that supplier from scratch and re-filing with regulators, while risking their own product in the meantime. So they do not. A specialty molecule takes years to get designed in, and once it is, it is just as slow to get designed out. That slowness is the whole moat, and it is why commodity and specialty players trade at completely different valuations.
The company reports record profit. Will it last? That depends entirely on where the profit came from. A jump driven by specialty, spec'd-in volumes is durable, because the customers are locked in and keep re-ordering. A jump driven by a commodity price spike is borrowed from the cycle; when supply catches up, the price falls and the profit goes with it. So before you admire a growth number, find out how much of the business is specialty and how much is commodity tonnage riding a good year.
Raw materials are mostly crude-oil derivatives and imported intermediates, a large share of them from China. When those input costs move, or Chinese supply floods or dries up, the spread between a chemical's selling price and its input cost moves with it. Gross spread, the margin left after raw materials, is where you see who has pricing power. A commodity player has almost none: costs rise, prices are set by the market, and the spread gets squeezed. A specialty player can hold its spread, because the locked-in customer absorbs a cost pass-through rather than re-qualify a new supplier.
A rival in China brings on a giant new plant. Does your caustic soda still command its price? No. When capacity floods the market, commodity prices collapse and thin margins turn straight into losses, and there is nothing a price-taker can do but wait. Even specialty players feel it when a molecule slowly drifts toward commodity as its patent protection fades and more suppliers qualify. The slower killers are customer concentration, where one big client de-specs you, and an environmental shutdown, where a pollution-control failure closes a plant overnight.
Management says the new plant will transform earnings. How do you check? Return on capital employed. Chemicals is capex-heavy, and a company can grow revenue for years just by pouring concrete and borrowing, while ROCE quietly sinks. The molecules that earn a genuinely high ROCE are the spec'd-in specialty ones; commodity tonnes rarely clear their cost of capital across a full cycle, however impressive the revenue line looks during a boom.
The best specialty and contract-manufacturing (CDMO) businesses, with locked-in customers and high ROCE, earn rich multiples, often 40-60 times earnings, the same premium a strong consumer brand gets, and for the same reason: dependable, hard-to-replace cash. Commodity chemical earnings deserve the opposite treatment. Value them on mid-cycle profit, never the peak, because a boom in a price-taken product always mean-reverts. The trap is paying a specialty multiple for peak commodity earnings.
Every sector reduces to a demand metric, a pricing metric, an efficiency metric, a capital metric, and a risk metric. For chemicals, these are the ones that matter.
What each number tells you, and how to read it.
| Metric | Why it matters |
|---|---|
| Specialty Revenue Mix | How much revenue is spec'd in versus commodity. The higher the specialty share, the more durable and less cyclical the earnings. |
| Gross Spread | Selling price minus raw-material cost. Commodity spreads swing with the cycle; specialty spreads hold because the customer is locked in. |
| EBITDA Margin | Operating profitability. Specialty and CDMO run 20-25%+; commodity is thin and cyclical. |
| ROCE | Capital efficiency. Chemicals is capex-heavy; ROCE across a full cycle separates value-creating molecules from concrete-pouring growth. |
| Capacity Utilisation | How full the plants are. Heavy fixed costs mean profits swing hard with utilisation. |
| Customer / Product Concentration | Dependence on a few clients or molecules. Concentration is the de-spec risk. |
| Export Share / China+1 Wins | Exposure to global buyers diversifying supply away from China, the structural tailwind for Indian specialty makers. |
Chemicals is two businesses in one lab coat: commodity molecules sell a price the world sets, while specialty molecules sell a spec the customer cannot easily replace.